Digestive Diseases and Sciences

, Volume 64, Issue 1, pp 93–101 | Cite as

Resveratrol Improves Recovery and Survival of Diet-Induced Obese Mice Undergoing Extended Major (80%) Hepatectomy

  • Xiaoling Jin
  • Teresa A. Zimmers
  • Zongxiu Zhang
  • Leonidas G. KoniarisEmail author
Original Article



Loss of hepatic epidermal growth factor receptor (EGFR) expression is a cause for the increased perioperative risk for complications and death in patients with obesity and fatty liver undergoing liver resection. Herein, we set out to identify agents that might increase EGFR expression and improve recovery for patients with fatty liver undergoing resection. Using the diet-induced obese (DIO) mouse model of fatty liver, we examined resveratrol as a therapy to induce EGFR expression and improve outcomes following 80% partial hepatectomy (PH) in a murine model.


DIO mice were fed resveratrol or carrier control by gavage. EGFR expression and the response to major (80%) PH were examined.


Based on an Illumina analysis, resveratrol was identified as increasing EGFR gene expression in A549 cells. Resveratrol was observed to also increase EGFR protein expression in A549 cells. DIO mice fed resveratrol by gavage (75 mg/kg) demonstrated an increased EGFR expression without the identified hepatic toxicity. Resveratrol and control mice subjected to 80% PH, a model of high mortality hepatectomy in DIO mice, demonstrated macroscopically decreased fatty liver and fewer liver hemorrhagic petechiae. Resveratrol pretreatment ameliorated liver injury and accelerated regeneration of the hepatic remnant after 80% PH including decreasing serum ALT and bilirubin, while increasing hepatic PCNA expression. Resveratrol increased induction of p-STAT3 and p-AKT after 80% hepatectomy. Resveratrol pretreatment significantly improved survival rates in DIO mice undergoing extended 80% PH.


Oral resveratrol restores EGFR expression in fatty liver. Resveratrol may be a promising protective agent in instances where extensive hepatic resection of fatty liver is required.


Liver regeneration Fatty liver Cytokines Hepatectomy Epidermal growth factor receptor Liver surgery 



Epidermal growth factor


Mitogen-activated protein kinase




Proliferating cell nuclear antigen


Signal transducer and activator of transcription


Diet-induced obese



This work was supported by the Lilly Endowment, Inc. Physician Scientist Initiative and National Institutes of Health Grants GM6360301 (L.G.K.), CA122596 and GM092758 (T.A.Z.).

Author’s contribution

Jin, Zimmers, and Koniaris were involved in the concept and design; Jin, Zhang, and Zimmers conducted the experiments; Jin, Zimmers, Zhang, and Koniaris interpreted the data; Jin, Koniaris, and Zimmers drafted the manuscript; Jin, Zimmers, Zhang, and Koniaris were involved in critical revisions.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Behrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg. 1998;2:292–298.CrossRefGoogle Scholar
  2. 2.
    Koniaris LG, McKillop IH, Schwartz SI, Zimmers TA. Liver regeneration. J Am Coll Surg. 2003;197:634–659.CrossRefGoogle Scholar
  3. 3.
    Koniaris LG, Levi DM, Pedroso FE, et al. Is surgical resection superior to transplantation in the treatment of hepatocellular carcinoma? Ann Surg. 2011;254:527–537. (discussion 537–528).CrossRefGoogle Scholar
  4. 4.
    Murata H, Yagi T, Iwagaki H, et al. Mechanism of impaired regeneration of fatty liver in mouse partial hepatectomy model. J Gastroenterol Hepatol. 2007;22:2173–2180.CrossRefGoogle Scholar
  5. 5.
    Torbenson M, Yang SQ, Liu HZ, Huang J, Gage W, Diehl AM. STAT-3 overexpression and p21 up-regulation accompany impaired regeneration of fatty livers. Am J Pathol. 2002;161:155–161.CrossRefGoogle Scholar
  6. 6.
    Yang SQ, Lin HZ, Mandal AK, Huang J, Diehl AM. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology. Hepatology. 2001;34:694–706.CrossRefGoogle Scholar
  7. 7.
    Gu Y, Sowa J-P, Paul A, Gerken G, Schlaak JF. Vascular endothelial growth factor improves liver regeneration and survival after 90% hepatectomy in a rat model of diet-induced steatosis. Digestion. 2013;88:235–242.CrossRefGoogle Scholar
  8. 8.
    Newberry EP, Kennedy SM, Xie Y, et al. Altered hepatic triglyceride content after partial hepatectomy without impaired liver regeneration in multiple murine genetic models. Hepatology. 2008;48:1097–1105.CrossRefGoogle Scholar
  9. 9.
    Au ED, Desai AP, Koniaris LG, Zimmers TA. The MEK-inhibitor selumetinib attenuates tumor growth and reduces IL-6 expression but does not protect against muscle wasting in Lewis lung cancer cachexia. Front Physiol. 2016;7:682.PubMedGoogle Scholar
  10. 10.
    Jin X, Zimmers TA, Jiang Y, Milgrom DP, Zhang Z, Koniaris LG. Meloxicam increases epidermal growth factor receptor expression improving survival after hepatic resection in diet-induced obese mice. Surgery. 2018;163:1264–1271.CrossRefGoogle Scholar
  11. 11.
    Zimmers TA, Jin X, Zhang Z, Jiang Y, Koniaris LG. Epidermal growth factor receptor restoration rescues the fatty liver regeneration in mice. Am J Physiol Endocrinol Metab. 2017;313:E440–E449.CrossRefGoogle Scholar
  12. 12.
    Szkudelski T, Szkudelska K. Resveratrol and diabetes: from animal to human studies. Biochim Biophys Acta. 1852;2015:1145–1154.Google Scholar
  13. 13.
    Kulkarni SS, Canto C. The molecular targets of resveratrol. Biochim Biophys Acta. 1852;2015:1114–1123.Google Scholar
  14. 14.
    Kupershmidt I, Su QJ, Grewal A, et al. Ontology-based meta-analysis of global collections of high-throughput public data. PLoS ONE. 2010;5:e13066.CrossRefGoogle Scholar
  15. 15.
    Natsoulis G, Pearson CI, Gollub J, et al. The liver pharmacological and xenobiotic gene response repertoire. Mol Syst Biol. 2008;4:175.CrossRefGoogle Scholar
  16. 16.
    Giebeler A, Boekschoten MV, Klein C, et al. c-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice. Gastroenterology. 2009;137:297–308.CrossRefGoogle Scholar
  17. 17.
    Fielden MR, Brennan R, Gollub J. A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol Sci. 2007;99:90–100.CrossRefGoogle Scholar
  18. 18.
    Koniaris LG, Zimmers-Koniaris T, Hsiao EC, Chavin K, Sitzmann JV, Farber JM. Cytokine-responsive gene-2/IFN-inducible protein-10 expression in multiple models of liver and bile duct injury suggests a role in tissue regeneration. J Immunol. 2001;167:399–406.CrossRefGoogle Scholar
  19. 19.
    Jin X, Zhang Z, Beer-Stolz D, Zimmers TA, Koniaris LG. Interleukin-6 inhibits oxidative injury and necrosis after extreme liver resection. Hepatology. 2007;46:802–812.CrossRefGoogle Scholar
  20. 20.
    Jin X, Zimmers TA, Perez EA, Pierce RH, Zhang Z, Koniaris LG. Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. Hepatology. 2006;43:474–484.CrossRefGoogle Scholar
  21. 21.
    Zimmers TA, Jin X, Hsiao EC, et al. Growth differentiation factor-15: induction in liver injury through p53 and tumor necrosis factor-independent mechanisms. J Surg Res. 2006;130:45–51.CrossRefGoogle Scholar
  22. 22.
    Zimmers TA, Jin X, Gutierrez JC, et al. Effect of in vivo loss of GDF-15 on hepatocellular carcinogenesis. J Cancer Res Clin Oncol. 2008;134:753–759.CrossRefGoogle Scholar
  23. 23.
    Zimmers TA, Gutierrez JC, Koniaris LG. Loss of GDF-15 abolishes sulindac chemoprevention in the ApcMin/+ mouse model of intestinal cancer. J Cancer Res Clin Oncol. 2010;136:571–576.CrossRefGoogle Scholar
  24. 24.
    Zimmers TA, Gutierrez JC, Koniaris LG. NAG-1/GDF-15: no evidence for an inhibitory role in colon cancer? Gastroenterology. 2007;132:1204–1205.CrossRefGoogle Scholar
  25. 25.
    Jin X, Zimmers TA, Zhang Z, Pierce RH, Koniaris LG. Interleukin-6 is an important in vivo inhibitor of intestinal epithelial cell death in mice. Gut. 2010;59:186–196.CrossRefGoogle Scholar
  26. 26.
    Nakajima T, Moriguchi M, Katagishi T, et al. Premature telomere shortening and impaired regenerative response in hepatocytes of individuals with NAFLD. Liver Int. 2006;26:23–31.CrossRefGoogle Scholar
  27. 27.
    Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology. 1994;20:829–838.CrossRefGoogle Scholar
  28. 28.
    Zerrad-Saadi A, Lambert-Blot M, Mitchell C, et al. GH receptor plays a major role in liver regeneration through the control of EGFR and ERK1/2 activation. Endocrinology. 2011;152:2731–2741.CrossRefGoogle Scholar
  29. 29.
    Seki E, Kondo Y, Iimuro Y, et al. Demonstration of cooperative contribution of MET- and EGFR-mediated STAT3 phosphorylation to liver regeneration by exogenous suppressor of cytokine signalings. J Hepatol. 2008;48:237–245.CrossRefGoogle Scholar
  30. 30.
    Natarajan A, Wagner B, Sibilia M. The EGF receptor is required for efficient liver regeneration. Proc Natl Acad Sci USA. 2007;104:17081–17086.CrossRefGoogle Scholar
  31. 31.
    Hajighasem A, Farzanegi P, Mazaheri Z. Effects of combined therapy with resveratrol, continuous and interval exercises on apoptosis, oxidative stress, and inflammatory biomarkers in the liver of old rats with non-alcoholic fatty liver disease. Arch Physiol Biochem. 2018:1–8.
  32. 32.
    Wang Y, Jiang Y, Fan X, et al. Hepato-protective effect of resveratrol against acetaminophen-induced liver injury is associated with inhibition of CYP-mediated bioactivation and regulation of SIRT1-p53 signaling pathways. Toxicol Lett. 2015;236:82–89.CrossRefGoogle Scholar
  33. 33.
    Huang TH, Chen CC, Liu HM, Lee TY, Shieh SH. Resveratrol pretreatment attenuates concanavalin A-induced hepatitis through reverse of aberration in the immune response and regenerative capacity in aged mice. Sci Rep. 2017;7:2705.CrossRefGoogle Scholar
  34. 34.
    Chan CC, Cheng LY, Lin CL, Huang YH, Lin HC, Lee FY. The protective role of natural phytoalexin resveratrol on inflammation, fibrosis and regeneration in cholestatic liver injury. Mol Nutr Food Res. 2011;55:1841–1849.CrossRefGoogle Scholar
  35. 35.
    Kirimlioglu H, Ecevit A, Yilmaz S, Kirimlioglu V, Karabulut AB. Effect of resveratrol and melatonin on oxidative stress enzymes, regeneration, and hepatocyte ultrastructure in rats subjected to 70% partial hepatectomy. Transplant Proc. 2008;40:285–289.CrossRefGoogle Scholar
  36. 36.
    Okay E, Simsek T, Subasi C, et al. Cross effects of resveratrol and mesenchymal stem cells on liver regeneration and homing in partially hepatectomized rats. Stem Cell Rev. 2015;11:322–331.CrossRefGoogle Scholar
  37. 37.
    Kantartzis K, Fritsche L, Bombrich M, et al. Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Obes Metab. 2018;20:1793–1797.CrossRefGoogle Scholar
  38. 38.
    Fogacci F, Banach M, Cicero AFG. Resveratrol effect on patients with non-alcoholic fatty liver disease: a matter of dose and treatment length. Diabetes Obes Metab. 2018;20:1798–1799.CrossRefGoogle Scholar
  39. 39.
    Rahman A, Assifi MM, Pedroso FE, et al. Is resection equivalent to transplantation for early cirrhotic patients with hepatocellular carcinoma? A meta-analysis. J Gastrointest Surg. 2012;16:1897–1909.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Xiaoling Jin
    • 2
  • Teresa A. Zimmers
    • 1
  • Zongxiu Zhang
    • 2
  • Leonidas G. Koniaris
    • 1
    Email author
  1. 1.Department of SurgeryIndiana University School of MedicineIndianapolisUSA
  2. 2.Department of SurgeryThomas Jefferson University School of MedicinePhiladelphiaUSA

Personalised recommendations